Afficher la notice abrégée

Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection

dc.rights.licenseopenen_US
dc.contributor.authorMERIGLIER, E.
dc.contributor.authorRIVOISY, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHESSAMFAR, Mojgan
dc.contributor.authorBERNARD, N.
dc.contributor.authorAUREAU, I.
dc.contributor.authorLAPOIRIE, J.
dc.contributor.authorCONTIS, A.
dc.contributor.authorSACHER, F.
dc.contributor.authorSACRISTAN, B.
dc.contributor.authorLAHOUATI, M.
dc.contributor.authorPEDEBOSCQ, S.
dc.contributor.authorVANDENHENDE, M. A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOUCHET, Stephane
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.date.accessioned2021-03-01T13:56:05Z
dc.date.available2021-03-01T13:56:05Z
dc.date.issued2021-01-19
dc.identifier.issn0305-7453 (Print) 0305-7453en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26391
dc.description.abstractEnBACKGROUND: Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection. OBJECTIVES: To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. METHODS: This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines. RESULTS: Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2-6) days after starting treatment. All ECG abnormalities reversed 1-2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration. CONCLUSIONS: Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.
dc.language.isoENen_US
dc.title.enSafety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection
dc.title.alternativeJ Antimicrob Chemotheren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/jac/dkaa441en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33221868en_US
bordeaux.journalThe Journal of Antimicrobial Chemotherapyen_US
bordeaux.page482-486en_US
bordeaux.volume76en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03165515
hal.version1
hal.date.transferred2021-03-10T15:41:18Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=The%20Journal%20of%20Antimicrobial%20Chemotherapy&rft.date=2021-01-19&rft.volume=76&rft.issue=2&rft.spage=482-486&rft.epage=482-486&rft.eissn=0305-7453%20(Print)%200305-7453&rft.issn=0305-7453%20(Print)%200305-7453&rft.au=MERIGLIER,%20E.&RIVOISY,%20C.&HESSAMFAR,%20Mojgan&BERNARD,%20N.&AUREAU,%20I.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée